T1	intervention 63 87	iniparib plus paclitaxel
T2	control 95 111	paclitaxel alone
T3	total-participants 625 628	141
T4	eligibility 629 661	patients with Stage II-IIIA TNBC
T5	control-participants 721 723	47
T6	intervention-participants 810 812	46
T7	intervention-participants 859 861	48
T9	outcome-Measure 898 946	pathologic complete response (pCR) in the breast
T10	outcome 948 956	pCR rate
T11	cv-bin-percent 991 993	21
T12	iv-bin-percent 995 997	22
T13	iv-bin-percent 1003 1007	19 %
T14	outcome 1092 1116	pCR in breast and axilla
T15	cv-bin-percent 1118 1120	21
T16	iv-bin-percent 1122 1124	17
T17	iv-bin-percent 1130 1134	19 %
T18	outcome 1137 1158	best overall response
T19	cv-bin-percent 1174 1176	60
T20	iv-bin-percent 1178 1180	61
T21	iv-bin-percent 1186 1190	63 %
T22	outcome 1197 1221	breast conservation rate
T23	cv-bin-percent 1223 1225	53
T24	iv-bin-percent 1227 1229	54
T25	iv-bin-percent 1235 1239	50 %
T26	outcome 1290 1311	grade 3/4 neutropenia
T27	cv-bin-percent 1313 1314	4
T28	iv-bin-percent 1316 1317	0
T29	iv-bin-percent 1323 1327	10 %
T30	outcome 1330 1339	Grade 1/2
T31	cv-bin-percent 1341 1343	28
T32	iv-bin-percent 1345 1347	22
T33	iv-bin-percent 1353 1357	29 %
T34	outcome 1367 1387	grade 3/4 neuropathy
T35	cv-bin-abs 1364 1366	no
T8	control 696 699	PTX
